Pharmacy Blogs

ValueRich sues China Pharmaceutical, formerly Xian China Qinba Pharmaceutical MarketWatch (press release) ValueRich alleges ownership of 20% of the outstanding shares of China Pharmaceuticals "pursuant to a May 2009 Consulting Agreement (the `Consulting … and more »

ValueRich sues China Pharmaceutical, formerly Xian China Qinba Pharmaceutical – MarketWatch (press release)

ValueRich sues China Pharmaceutical, formerly Xian China Qinba Pharmaceutical MarketWatch (press release) ValueRich alleges ownership of 20% of the outstanding shares of China Pharmaceuticals "pursuant to a May 2009 Consulting Agreement (the `Consulting … and more »

ValueRich sues China Pharmaceutical, formerly Xian China Qinba Pharmaceutical – MarketWatch (press release)

Eurand Names Former Solvay Executive Jean-Louis Anspach President of U.S. … MarketWatch (press release) Anspach is a 25-year veteran of the specialty pharmaceutical and chemical industries and was most recently Executive Vice President, Marketing at Solvay … and more »

Eurand Names Former Solvay Executive Jean-Louis Anspach President of U.S. … – MarketWatch (press release)

Salix Pharmaceuticals to Present At NASDAQ Conference MarketWatch (press release) Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of … and more »

Salix Pharmaceuticals to Present At NASDAQ Conference – MarketWatch (press release)

Bizjournals.com

KV Pharmaceutical chairman, CFO, board member resign Bizjournals.com The chairman, chief financial officer and another board member of KV Pharmaceutical Co. have resigned, citing serious concerns about the newly elected board … KV Pharmaceutical Chairman, Chief Financial Officer and board member resign …KSDK all 3 news articles »

KV Pharmaceutical chairman, CFO, board member resign – Bizjournals.com

Pharmaceutical Product Development and Furiex Pharmaceuticals completes spin-off Trading Markets (press release) Partner 1 (Company) Furiex Pharmaceuticals, Inc. Partner 2 (Company) Pharmaceutical Product Development, Inc. For full details on Pharmaceutical Prod Dev … Pharmaceutical Product Development completes spinoff of FuriexLocal Tech Wire (blog) PPD and Furiex Announce Completion of Spin-OffMarketWatch (press release) PPD names Wilkinson chief information officerBusinessWeek StarNewsOnline.com -Triangle Business Journal all 67 news articles »

Pharmaceutical Product Development and Furiex Pharmaceuticals completes spin-off – Trading Markets (press release)

Teva Pharmaceutical launches $2.5 bln notes Reuters NEW YORK June 15 (Reuters) – Teva Pharmaceutical Finance BV and Teva Pharmaceutical III on Tuesday launched a combined $2.5 billion of notes in a three-part … Teva Announces Pricing of $2.5 Billion of Senior NotesMarketWatch (press release) Teva prices $2.5 billion in notes in offeringBusinessWeek S&P: Teva Pharmaceutical Industries Ltd. Rule 415 Shelf Issues Assigned 'A …PharmaLive.com (press release) Globes -International Financing Review -Stock Markets Review all 40 news articles »

Teva Pharmaceutical launches $2.5 bln notes – Reuters

Thallion Pharmaceuticals Receives Arbitration Decision on TLN-232 License … MarketWatch (press release) Thallion Pharmaceuticals Inc. (THE:CA:TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. …

Thallion Pharmaceuticals Receives Arbitration Decision on TLN-232 License … – MarketWatch (press release)

Missouri to get nearly $11M from drug settlements BusinessWeek Missouri is getting nearly $11 million as its share of a pair of national settlements with pharmaceutical companies. Attorney General Chris Koster says … Missouri Gets $9 Million in Pharmaceutical SuitOzarksFirst.com (blog) State reaches $1.7 million settlement with NovartisSpringfield Business Journal all 20 news articles »

Missouri to get nearly $11M from drug settlements – BusinessWeek

WASHINGTON – A pink pill designed to offer women a counterpart to Viagra failed to boost female sex drive in two studies, U.S. drug reviewers …
‘Pink Viagra’ fails to impress FDA